Does UnitedHealthcare Cover Forteo? A Woman's Complete Guide to Teriparatide Insurance Coverage

What Is Forteo and Why Do Women Use It?

Forteo is a brand-name injectable form of teriparatide, a synthetic fragment of human parathyroid hormone. Unlike bisphosphonates, which slow bone breakdown, teriparatide actively builds new bone. That distinction matters because women lose bone mass faster than men do at almost every life stage, and the anabolic mechanism makes Forteo one of the most effective options for severe or treatment-resistant osteoporosis.

The FDA approved teriparatide specifically for postmenopausal women with osteoporosis at high risk of fracture, as well as for men with primary or hypogonadal osteoporosis, and for women and men with glucocorticoid-induced osteoporosis.

Why Women Are the Primary Users

Women account for roughly 80 percent of the 10 million Americans who have osteoporosis, driven largely by estrogen loss at menopause. The rate of bone loss accelerates in the two to three years immediately before the final menstrual period and continues for up to a decade afterward. If you are in perimenopause or early postmenopause and your DEXA scan shows a T-score at or below -2.5, or if you have already had a fragility fracture, your clinician may recommend Forteo over an oral bisphosphonate.

Women with the following conditions are particularly likely to be candidates for Forteo:

• Postmenopausal osteoporosis with a T-score at or below -2.5 at the spine or hip
• Prior vertebral or hip fracture
• Glucocorticoid-induced bone loss (common in women with autoimmune conditions such as lupus or rheumatoid arthritis)
• Bisphosphonate failure or true intolerance (esophageal disorders, severe GI side effects)
• Premenopausal osteoporosis (off-label; less evidence available)

The Menopause Connection

Estrogen normally restrains osteoclast activity. When estrogen drops at menopause, bone resorption outpaces formation. Women can lose up to 20 percent of their bone density in the five to seven years following menopause. Teriparatide counteracts this by directly stimulating osteoblasts, the cells that build bone matrix. The landmark FPT (Fracture Prevention Trial) showed that 20 mcg/day reduced new vertebral fractures by 65 percent in postmenopausal women over a median of 21 months.

How UnitedHealthcare Covers Forteo

UnitedHealthcare (UHC) covers Forteo under the specialty pharmacy benefit for most commercial, Medicare Advantage, and employer-sponsored plans, but the specific rules depend on your exact plan document.

Commercial Plans (Employer-Sponsored and Individual Marketplace)

On most commercial UHC plans, Forteo sits on a Specialty Tier (Tier 4 or Tier 5). Before your claim is approved, the plan's pharmacy benefit manager, OptumRx, typically requires:

1. A diagnosis of osteoporosis confirmed by DEXA, with T-score at or below -2.5, OR a documented low-trauma fracture
2. An inadequate response to, or documented intolerance of, at least one oral bisphosphonate (usually alendronate or risedronate for a minimum of three to six months)
3. A prescription from a physician, NP, or PA with appropriate specialty designation
4. Documentation that the treatment duration will not exceed 24 months cumulative lifetime use

UHC's medical and pharmacy policies are updated quarterly, so the specific criteria may shift. Always pull your plan's current Evidence of Coverage document and the corresponding OptumRx drug policy before submitting.

Medicare Advantage Plans

Medicare Advantage coverage for Forteo varies by plan. Most UHC Medicare Advantage plans place teriparatide on a specialty tier with a prior authorization requirement identical to commercial plans. Under Medicare Part D, Forteo is subject to the standard coverage gap rules, although the Inflation Reduction Act has begun phasing in a $2,000 annual out-of-pocket cap for Part D beneficiaries starting in 2025. CMS finalized this cap as part of the IRA's Part D redesign effective January 1, 2025, which meaningfully reduces the catastrophic cost burden for postmenopausal women on specialty bone-building drugs.

Medicaid

UHC manages Medicaid plans in several states. Teriparatide coverage under Medicaid is far less consistent. Some state formularies exclude it outright; others allow it with prior authorization. If you are on UHC Medicaid, call the member number on your card and ask specifically whether teriparatide appears on the state's preferred drug list.

Prior Authorization: What UHC Requires and How to Get It

Prior authorization (PA) is the single biggest barrier women face when trying to access Forteo. Understanding exactly what the insurer needs makes the difference between a 72-hour approval and a months-long fight.

Step 1: Get the Right Documentation From Your Clinician

Your prescribing clinician needs to submit a PA request that includes:

• Your most recent DEXA scan report (within 24 months), listing specific T-scores at the lumbar spine (L1-L4) and total hip or femoral neck
• Documentation of your fracture history, if applicable, including imaging reports
• A clear record of prior bisphosphonate therapy: the drug name, dose, duration, and reason for stopping (inadequate response, intolerance, or contraindication)
• A clinical statement explaining why teriparatide is medically necessary for you specifically

Step 2: Ask for the Specific PA Form

OptumRx uses a specific prior authorization form for bone-building agents. Your prescriber's office can download it from the OptumRx provider portal or call OptumRx Provider Services directly. Using the correct form matters because missing fields are the most common reason for automatic denial.

Step 3: Follow Up Within 72 Hours

Standard PA decisions for non-urgent requests must be made within 72 hours under most state insurance regulations. Urgent requests (for example, if you have had a recent fracture) must be decided within 24 hours. Call UHC member services if you have not received a decision within that window.

Step 4: Prepare for Step Therapy

Step therapy means the insurer requires you to try and fail a lower-cost drug before they will approve the preferred drug. For Forteo, this almost always means trying at least one oral bisphosphonate first. If you have a documented contraindication to bisphosphonates (for example, active esophageal disease, severe chronic kidney disease with GFR <35 mL/min/1.73m², or a prior atypical femoral fracture on bisphosphonates) your clinician should document that contraindication explicitly in the PA request to bypass step therapy.

What to Do If UHC Denies Your Forteo Claim

Denials happen. They are not final. Here is what to do in order.

Internal Appeal

You have the right to file an internal appeal with UHC within 180 days of a denial (60 days for Medicare Advantage). Your clinician should write a letter of medical necessity that directly addresses the reason for denial listed on your Explanation of Benefits. Common denial reasons and responses include:

• "Step therapy not completed": Submit documentation of prior bisphosphonate use or the specific contraindication
• "Not medically necessary": Attach the DEXA report, fracture history, and a peer-reviewed clinical guideline such as the American Association of Clinical Endocrinology 2020 Osteoporosis Clinical Practice Guidelines supporting anabolic therapy for high-risk patients
• "Duration limit exceeded": Confirm that prior teriparatide use (if any) is accurately documented

External Review

If the internal appeal fails, you can request an independent external review. Under the ACA, insurers must comply with external reviewer decisions. External review is free and must be completed within 45 days (or 72 hours for expedited reviews).

State Insurance Commissioner Complaint

Filing a complaint with your state insurance commissioner puts pressure on the insurer to re-examine the denial. It also creates a public record, which matters for regulators tracking patterns of inappropriate step therapy.

Forteo Cost and Patient Assistance Programs

Even with insurance, specialty tier cost-sharing can be significant. Without assistance, Forteo's list price is approximately $8,000 to $9,000 per month.

Eli Lilly's Forteo Savings Card

Eli Lilly offers a savings card for commercially insured patients (not eligible for Medicare or Medicaid). Eligible patients may pay as little as $4 per month per fill for up to 24 months of therapy. This is not a co-pay card in the traditional sense: it functions as a secondary payer that covers most of the remaining cost-share after insurance. To qualify, you must be insured through a commercial plan (not government-funded), and your plan must cover Forteo. You can enroll at the Lilly Cares website or ask your pharmacist to apply the card at the point of dispensing.

A practical framework to minimize Forteo out-of-pocket costs, in order of steps to try:

1. Confirm your plan covers Forteo before the prescription is written (call OptumRx at the number on your insurance card and ask for the formulary tier and PA requirements).
2. Have your prescriber submit the PA with complete documentation the first time.
3. Enroll in the Lilly savings card before your first fill.
4. If you are denied, file the internal appeal with a letter of medical necessity citing named clinical guidelines.
5. If coverage is still denied, ask your clinician whether abaloparatide (Tymlos) or romosozumab (Evenity) might be covered under your plan as alternatives.

NeedyMeds and the Patient Advocate Foundation

If you are uninsured or your savings card is insufficient, NeedyMeds maintains a database of disease-specific co-pay assistance programs. The Patient Advocate Foundation provides case managers who can negotiate directly with insurers on your behalf, free of charge.

Forteo Alternatives UHC May Cover Instead

If UHC denies Forteo specifically, these agents may be on a more favorable tier for your plan.

| Drug (Generic) | Mechanism | Who It Is Typically Approved For | |---|---|---| | Alendronate (Fosamax) | Antiresorptive bisphosphonate | First-line; oral weekly | | Risedronate (Actonel) | Antiresorptive bisphosphonate | First-line; oral weekly or monthly | | Denosumab (Prolia) | RANK-L inhibitor | Postmenopausal women; renal impairment | | Abaloparatide (Tymlos) | Anabolic PTHrP analog | High-fracture-risk postmenopausal women | | Romosozumab (Evenity) | Dual anabolic/antiresorptive | High-fracture-risk postmenopausal women; cardiovascular caution | | Zoledronic acid (Reclast) | IV bisphosphonate | Annual infusion; GI intolerance |

Abaloparatide and romosozumab are newer anabolic or dual-action agents. The ACTIVE trial showed abaloparatide reduced vertebral fractures by 86 percent versus placebo in postmenopausal women, a result comparable to teriparatide's FPT data. If UHC's formulary places abaloparatide on a lower tier than Forteo, that may be a clinically appropriate and more accessible alternative.

Pregnancy, Lactation, and Contraception Considerations

This section is required reading if you are of reproductive age and being considered for Forteo.

Pregnancy: Forteo Is Contraindicated

Teriparatide carries a Black Box Warning regarding osteosarcoma risk, based on rat studies showing dose-dependent osteosarcoma at exposures greater than three to sixty times the human dose. No equivalent human data exist, and osteosarcoma has not been confirmed in post-marketing surveillance, but the FDA label and ACOG's guidance on medications in pregnancy maintain a contraindication in pregnancy as a precautionary measure.

If you are pregnant or actively trying to conceive, Forteo should not be started. If you become pregnant while on Forteo, discontinue immediately and notify your obstetric provider. There is no established human teratogenicity data from controlled trials, because pregnant women are appropriately excluded from osteoporosis trials.

What Women of Reproductive Age Should Know

Premenopausal osteoporosis is rare but real, occurring most often in women with anorexia nervosa, athletic amenorrhea (relative energy deficiency in sport), premature ovarian insufficiency, or long-term glucocorticoid use. Evidence in premenopausal women is extrapolated almost entirely from postmenopausal trials, and the FDA label does not carry a premenopausal indication for teriparatide. The data gap here is real and should be named: if you are premenopausal and your clinician recommends Forteo, that is an off-label use based on extrapolated evidence, not a direct study in your population.

Reliable contraception is essential during teriparatide treatment for any woman who is not postmenopausal or surgically sterile.

Lactation

No human data exist on teriparatide transfer into breast milk. Because the drug is a peptide (84 amino acid fragment), it would likely be degraded in the infant's gut even if present in milk. Regardless, the manufacturer advises against use during breastfeeding due to the absence of safety data. If you are postpartum and breastfeeding with severe bone loss (for example, pregnancy and lactation-associated osteoporosis), discuss the risk-benefit ratio explicitly with your clinician. Calcium and vitamin D supplementation remain the foundation during lactation, with referral to a metabolic bone specialist for severe cases.

Who Is Right for Forteo and Who Is Not

Right for Forteo

• Postmenopausal women with T-score at or below -2.5 and at least one additional fracture risk factor, or a prior fragility fracture
• Women who have tried bisphosphonates for at least one year and have continued bone loss or a new fracture on therapy
• Women with glucocorticoid-induced osteoporosis on prednisone >5 mg/day for three or more months
• Women with documented bisphosphonate intolerance or contraindication

Not Right for Forteo

• Pregnant women or women trying to conceive (contraindicated)
• Women with a prior history of bone metastases, skeletal malignancy, or Paget's disease (increased baseline bone turnover contraindicated on label)
• Women who have had prior radiation therapy involving the skeleton
• Women with unexplained elevated alkaline phosphatase
• Women who have already completed 24 months of teriparatide or abaloparatide (no additional benefit and potential increased risk)
• Women with severe hypercalcemia

Life-Stage Summary: Forteo Across a Woman's Life

Reproductive years (18 to 45): Forteo is rarely indicated. If bone loss is severe and premenopausal, the cause (eating disorder, athletic amenorrhea, glucocorticoid use, POI) should be treated first. Off-label use only, with mandatory contraception. Evidence is extrapolated, not direct.

Perimenopause (approximately 45 to 55): The years of fastest bone loss. Hormone therapy can be the preferred first intervention for bone preservation if you are also managing vasomotor symptoms. The Menopause Society (formerly NAMS) 2023 position statement supports hormone therapy as effective for fracture prevention in women under 60. Forteo is reserved for women with established osteoporosis or fractures, not for prevention alone.

Postmenopause (55 and older): The primary indication for Forteo. Coverage through UHC is most straightforward in this group because the FDA-approved population and the insurer's PA criteria align. DEXA every one to two years after starting therapy to document response.

Post-Forteo transition: Because stopping teriparatide causes rapid bone loss reversal, sequential antiresorptive therapy is required. Most guidelines, including The Endocrine Society's 2020 clinical practice guideline, recommend transitioning directly to denosumab or a bisphosphonate within one to three months of completing the 24-month course.

As WomanRx Medical Reviewer Rachel Goldberg, MD, notes: "The biggest mistake I see women make after completing Forteo is assuming the work is done. Without immediate transition to an antiresorptive agent, the bone you built can be lost within 12 to 18 months. The coverage fight for Forteo is worth it, but the follow-on coverage for denosumab or zoledronic acid matters just as much."

A Practical Checklist Before Calling UHC

Use this before your first call to OptumRx or UHC member services:

• [ ] Pull your plan's Summary of Benefits and Coverage (SBC) and look up the specialty tier co-pay or co-insurance percentage
• [ ] Ask specifically: "Is teriparatide (Forteo) on the formulary, and what tier?"
• [ ] Ask: "What is the prior authorization criteria document number for teriparatide?"
• [ ] Request the PA form number so your prescriber's office uses the correct version
• [ ] Confirm the specialty pharmacy that handles Forteo under your plan (usually OptumRx Specialty)
• [ ] Ask whether abaloparatide (Tymlos) is on the same tier or a lower tier
• [ ] Write down the name of every representative you speak with, along with the date and reference number